 |
|
A Nationwide Study of Decisions to Forego Life-Prolonging Treatment in Dutch Medical Practice
Johanna H. Groenewoud, MD;
Agnes van der Heide, MD, PhD;
John G. C. Kester, MA;
Carmen L. M. de Graaff, MA;
Gerrit van der Wal, MD, PhD;
Paul J. van der Maas, MD, PhD
Arch Intern Med. 2000;160:357-363.
Background Decisions to withhold or withdraw life-prolonging treatment in terminally ill patients are common in some areas of medical practice. Information about the frequency and background of these decisions is generally limited to specific clinical settings. This article describes the practice of withholding or withdrawing life-prolonging treatment in the Netherlands.
Methods Questionnaires were sent to the attending physicians of a stratified sample of 6060 of all 43,002 cases of death in the Netherlands from August 1 through November 30, 1995. The questions concerned the treatments foregone, the patient characteristics, and the decision-making process. The response rate was 77%.
Results A nontreatment decision was made in 30% (95% confidence interval, 28%-31%) of all deaths in the Netherlands in 1995; this is an increase compared with 28% (95% confidence interval, 26%-29%) in 1990; in 20% of all deaths, this decision was the most important end-of-life decision. Artificial nutrition or hydration and antibiotics were the treatments most frequently foregone, each accounting for 25% of cases in which a nontreatment decision was made. Nursing-home physicians withheld or withdrew treatment more often than clinical specialists or general practitioners in 52%, 35%, and 17% of all deaths they were involved with, respectively. Of the patients in whom a nontreatment decision was the most important end-of-life decision, 26% were competent; of those, 93% were involved in the decision making. In 17% of patients, the nontreatment decision was made without being discussed with the patient or the patient's relatives and without knowledge of the patient's wishes. Life was shortened by an estimated 24 hours or less in 42% and 1 month or more in 8% of patients.
Conclusions Decisions to forego life-prolonging treatment are frequently made end-of-life decisions in the Netherlands and may be increasing. Most of these decisions do not involve high-technology treatments, and the consequences, in terms of shortening of life, are relatively small.
From the Department of Public Health, Erasmus University Rotterdam (Drs Groenewoud, van der Heide, and van der Maas), Statistics Netherlands, Voorburg (Mr Kester and Ms de Graaff), Institute for Research in Extramural Medicine and Department of Social Medicine, Vrije Universiteit Amsterdam, the Netherlands.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(3):397-398.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Autonomy at the end of life: life-prolonging treatment in nursing homes--relatives' role in the decision-making process
Dreyer et al.
J. Med. Ethics 2009;35:672-677.
ABSTRACT
| FULL TEXT
Nurses' attitudes towards artificial food or fluid administration in patients with dementia and in terminally ill patients: a review of the literature
Bryon et al.
J. Med. Ethics 2008;34:431-436.
ABSTRACT
| FULL TEXT
Restriction of Ongoing Intensive Care in Neonates: A Prospective Study
Hentschel et al.
Pediatrics 2006;118:563-569.
ABSTRACT
| FULL TEXT
Forgoing Treatment at the End of Life in 6 European Countries
Bosshard et al.
Arch Intern Med 2005;165:401-407.
ABSTRACT
| FULL TEXT
Medical decision making in scarcity situations
van Delden et al.
J. Med. Ethics 2004;30:207-211.
ABSTRACT
| FULL TEXT
Stagnation in Mortality Decline Among Elders in The Netherlands
Janssen et al.
Gerontologist 2003;43:722-734.
ABSTRACT
| FULL TEXT
|
